- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Medical Research
Lilly collaboration with outside researchers yields first deal
February 8, 2011
Chris O'MalleyEli Lilly and Co.'s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz
said it's just the first of many such collaborations.
MoreEndocyte again changes terms of public offering
February 4, 2011
IBJ Staff and Bloomberg NewsThe West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more
than previously announced, but at a lower price of $6 each.
MorePotential competitor to Lilly drug shows promise in study
February 2, 2011
IBJ Staff and Bloomberg NewsSanofi-Aventis's experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective
as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.'s twice-daily medicine Byetta, a study found.
MoreCarmel firm gets FDA approval for lice treatment
January 18, 2011
IBJ StaffParaPRO LLC's treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
MoreLilly imaging drug isn't ready for approval, FDA says
January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval,
according to U.S. regulators.
MoreLilly's Solpura may lack data to prove effectiveness
January 10, 2011
Bloomberg NewsOutside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency
caused by cystic fibrosis, chronic pancreatitis or other conditions.
MoreLilly, other big drugmakers shut out by FDA in 2010
January 3, 2011
IBJ Staff and Bloomberg NewsRegulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer
Inc., the world's largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same
time, according to agency records.
MoreRoche acquires Marcadia Biotech
December 30, 2010
Chris O'MalleyMarcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in
2006, has been acquired by Swiss life sciences giant Roche.
MoreLilly suspends late-stage trial for melanoma drug
December 13, 2010
Bloomberg NewsEli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study
died.
MoreQ&A
December 8, 2010
J.K. WallMolecular biologist,David G. Skalnik will become associate dean for research and graduate education at the
IUPUI School of Science in January. Since 1991, Skalnick has been a researcher at the Indiana University School of Medicine,
leading a team of three in the study of epigenetics—factors that influence whether certain genes are turned on or turned
off.
MoreLilly, Acrux receive FDA approval for Axiron
November 24, 2010
IBJ Staff and Bloomberg NewsThe companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year
in the United States.
MoreStudy: Arthritis drug co-developed by Lilly shows promise
November 12, 2010
IBJ Staff and Bloomberg NewsLilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications
for autoimmune diseases.
MoreLilly makes $300M deal for Philadelphia drug company
November 8, 2010
J.K. WallEli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients
with Alzheimer's disease. The price could climb to $800 million if the agent is commercially successful.
MoreUPDATE: Lilly, others see stock slide after drug rejection
October 20, 2010
Bloomberg NewsStock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in
a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
MoreIU shrink explores mental health blood tests
October 13, 2010
J.K. WallDr. Alexander B. Niculescu, a psychiatrist at the IU School of Medicine, has won a five-year, $1.5 million grant from the
National Institutes of Health to hunt for the presence of certain proteins in the blood that would indicate that a patient
suffers from a mood disorder, which afflicts one in five Americans.
MoreCook stent could prevent more amputations, study finds
September 27, 2010
Bloomberg NewsA drug-coated stent from Indiana-based Cook Medical was more effective than standard therapy for patients with blockages in
an upper-leg artery, a study found.
MoreAfter health reform, Lilly looking for more
September 1, 2010
J.K. WallThe health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives
of the
bill—and calling for further government efforts to help pharmaceutical research and development.
MorePearl IRB first firm in state to pre-screen clinical drug trials
August 21, 2010
Chris O'MalleyTwo former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
MoreCancer drug developer Endocyte files for IPO
August 18, 2010
Scott OlsonThe company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
MoreLilly Alzheimer's drug prospect only the latest to fail
August 18, 2010
Bloomberg NewsA dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
MoreLilly halts development of Alzheimer's drug
August 17, 2010
IBJ Staff and Associated PressStudies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
MoreIndiana universities offer cash incentives for technology transfer
August 7, 2010
IBJ StaffThe Indiana Clinical and Translational Sciences Institute awarded $750,000 to 10 teams of researchers.
MoreLilly's Alzheimer's gamble takes aim at $10 billion in patent losses
July 13, 2010
Bloomberg NewsBoth of Lilly's late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer's. A drug that stops or reduces memory loss caused by Alzheimer's may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
MoreQ&A
June 23, 2010
J.K. WallDavid Stocum is the director of the Center for Regenerative Biology and Medicine at the IUPUI School of Science.
He and his team are studying how amphibians regenerate parts of their bodies to see if there are ways to induce humans to
regenerate tissue that is lost or damaged. The center has about 20 researchers and funding of about $14 million to fuel its
quest.
MoreGenetic testing could spur Erbitux drug sales
June 1, 2010
Bloomberg NewsThe drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
It's also across the street from Fogo de Chao and Morton's....
Yep, the haters are trying to make good news bad. I guess it is hard to get people to believe the series is dying when they are gaining new sponsors.
David Copperfield! I remember watching his specials on TV when I was little.
Don't forget this is next to an MMA gym, a pawn shop, and some abandoned spaces.
Good project for Zionsville - A group who has owned the property for many years has waited and worked patiently to bring highest and best use development to a major corridor, and mix that in with the great downtown you have. Win Win. All the Best to Pittman Partners and Zionsville.